aniracetam
Sign in to saveAniracetam (brand names Draganon, Sarpul, Ampamet, Memodrin, Referan), also known as '''N-anisoyl-2-pyrrolidinone''', is a racetam which is sold in Europe as a prescription drug. It is not approved by the Food and Drug Administration for use in the United States as a prescription medication or dietary supplement. Despite the FDA's lack of approval, the drug is readily available over-the-counter in misbranded dietary supplements.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477164594
- Drug.IUPAC_name
- 1-[(4-Methoxybenzoyl)]-2-pyrrolidinone
- Drug.image
- Aniracetam.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Aniracetam3d.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 175
- Drug.tradename
- Ampamet, Memodrin, Pergamid
- Drug.legal_US_comment
- Unapproved "New Drug" (as defined by 21 U.S. Code § 321(p)(1)). Use in dietary supplements, food, or medicine is unlawful; otherwise uncontrolled.
- Drug.legal_AU
- S4
- Drug.routes_of_administration
- By mouth
- Drug.elimination_half life
- 0.5 hours
- Drug.IUPHAR_ligand
- 4133
- Drug.CAS_number
- 72432-10-1
- Drug.ATC_prefix
- N06
via Wikipedia infobox
Research
320 papers- Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.CNS drug reviews · 2002
- Aniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice.eNeuro · 2025
- Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.Drugs & aging · 1994
- Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024
- Aniracetam does not improve working memory in neurologically healthy pigeons.PloS one · 2019
via PubMed
Article
8 sectionsContents
- Medical uses
- Pharmacology
- Synthesis
- Legality
- Europe
- Australia
- See also
- References
Aniracetam (brand names Draganon, Sarpul, Ampamet, Memodrin, Referan), also known as '''N-anisoyl-2-pyrrolidinone''', is a racetam which is sold in Europe as a prescription drug. It is not approved by the Food and Drug Administration for use in the United States as a prescription medication or dietary supplement. Despite the FDA's lack of approval, the drug is readily available over-the-counter in misbranded dietary supplements.
== Medical uses == Aniracetam has been used to treat dementia following stroke and in Alzheimer's disease. Results from human clinical trials were published in 1991 (one multi-center placebo-controlled study and a follow-up) and in 2011 (one open-label study).